Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma

Anubha Arora, Vijaya R Bhatt, Susanne Liewer, James Olen Armitage, Robert G Bociek

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29-yr-old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic reaction during the second dose of brentuximab vedotin. A 12-step desensitization protocol was followed; after premedicating with antihistaminic agents, methylprednisolone and montelukast, a total dose of 156mg of brentuximab vedotin (1.8mg/kg) was given as three infusions with increasing rate and concentration. Such desensitization protocol can allow safe administration of brentuximab vedotin and may have a broader applicability in managing hypersensitivity reactions with other monoclonal antibodies.

Original languageEnglish (US)
Pages (from-to)361-364
Number of pages4
JournalEuropean Journal of Haematology
Volume95
Issue number4
DOIs
StatePublished - Oct 1 2015

Fingerprint

Hodgkin Disease
montelukast
Anaphylaxis
Methylprednisolone
Hypersensitivity
Monoclonal Antibodies
cAC10-vcMMAE
Therapeutics

Keywords

  • Anaphylaxis
  • Brentuximab vedotin
  • Desensitization
  • Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma. / Arora, Anubha; Bhatt, Vijaya R; Liewer, Susanne; Armitage, James Olen; Bociek, Robert G.

In: European Journal of Haematology, Vol. 95, No. 4, 01.10.2015, p. 361-364.

Research output: Contribution to journalArticle

@article{eeb1bdbefcf041f6bc1d3d6a7b01112a,
title = "Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma",
abstract = "Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29-yr-old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic reaction during the second dose of brentuximab vedotin. A 12-step desensitization protocol was followed; after premedicating with antihistaminic agents, methylprednisolone and montelukast, a total dose of 156mg of brentuximab vedotin (1.8mg/kg) was given as three infusions with increasing rate and concentration. Such desensitization protocol can allow safe administration of brentuximab vedotin and may have a broader applicability in managing hypersensitivity reactions with other monoclonal antibodies.",
keywords = "Anaphylaxis, Brentuximab vedotin, Desensitization, Hodgkin's lymphoma",
author = "Anubha Arora and Bhatt, {Vijaya R} and Susanne Liewer and Armitage, {James Olen} and Bociek, {Robert G}",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/ejh.12570",
language = "English (US)",
volume = "95",
pages = "361--364",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma

AU - Arora, Anubha

AU - Bhatt, Vijaya R

AU - Liewer, Susanne

AU - Armitage, James Olen

AU - Bociek, Robert G

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29-yr-old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic reaction during the second dose of brentuximab vedotin. A 12-step desensitization protocol was followed; after premedicating with antihistaminic agents, methylprednisolone and montelukast, a total dose of 156mg of brentuximab vedotin (1.8mg/kg) was given as three infusions with increasing rate and concentration. Such desensitization protocol can allow safe administration of brentuximab vedotin and may have a broader applicability in managing hypersensitivity reactions with other monoclonal antibodies.

AB - Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29-yr-old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic reaction during the second dose of brentuximab vedotin. A 12-step desensitization protocol was followed; after premedicating with antihistaminic agents, methylprednisolone and montelukast, a total dose of 156mg of brentuximab vedotin (1.8mg/kg) was given as three infusions with increasing rate and concentration. Such desensitization protocol can allow safe administration of brentuximab vedotin and may have a broader applicability in managing hypersensitivity reactions with other monoclonal antibodies.

KW - Anaphylaxis

KW - Brentuximab vedotin

KW - Desensitization

KW - Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84946169389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946169389&partnerID=8YFLogxK

U2 - 10.1111/ejh.12570

DO - 10.1111/ejh.12570

M3 - Article

C2 - 25892213

AN - SCOPUS:84946169389

VL - 95

SP - 361

EP - 364

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -